Article

Sight Sciences’ TRAB360 Effective in Single-Center Study

■ A new, single-center retrospective study of glaucoma surgery patients shows that ab-interno trabeculotomy using the Sight Sciences OMNI Surgical System predicate device (TRAB360) provides a favorable safety profile and substantial long-term reductions in both IOP and IOP-lowering medications. The data were published in a recent issue of Clinical Ophthalmology.

Conducted by Steven Sarkisian, MD, from the Dean A. McGee Eye Institute, the consecutive case series included data on a total of 81 eyes from 69 glaucoma patients undergoing standalone microinvasive trabeculotomy. Nearly two-thirds of the eyes (50/81, 61.7%) had undergone prior glaucoma surgery. At 12 months there was a 7.3 mmHg mean IOP reduction from a mean medicated baseline IOP of 23.7 mmHg to a mean 12-month IOP of 15.7 mmHg. Seven percent of eyes with preoperative IOP values of ≥25 mmHg achieved ≥20% reduction in IOP and IOP <18 mmHg with the same or fewer numbers of IOP-lowering medications compared with those at baseline. The most common adverse event was transient hyphema (50.6%); 90% of these cases were classified as mild.

“The findings of this study are consistent with the historical body of literature on the long-term safety and efficacy of circumferential trabeculotomy in adults,” said Dr. Sarkisian. “Performed in a tertiary care setting, these surgeries represent an advanced and clinically diverse patient population including POAG, pigmentary glaucoma, congenital glaucoma, neovascular glaucoma, and other types of glaucoma.”

The OMNI Surgical System, initially launched in February 2018, combines the distinct functions of its 2 predicate devices — TRAB360 for trabeculotomy and VISCO360 for transluminal viscoelastic delivery — into 1 device so that all 3 sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm’s canal, and collector channels) can be targeted with a single device and single surgery. At the recent Association for Research in Vision and Ophthalmology meeting, Sight Sciences launched an aesthetically and ergonomically enhanced OMNI Surgical System.